Compare RENX & VIVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RENX | VIVS |
|---|---|---|
| Founded | 2021 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.7M | 3.8M |
| IPO Year | 2023 | 2010 |
| Metric | RENX | VIVS |
|---|---|---|
| Price | $1.97 | $0.20 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 118.5K | ★ 587.7K |
| Earning Date | 11-13-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $8,220,449.00 | $4,603,000.00 |
| Revenue This Year | $109.28 | $228,144.28 |
| Revenue Next Year | $53.56 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 3860.67 | 8.82 |
| 52 Week Low | $0.09 | $0.19 |
| 52 Week High | $3.48 | $3.54 |
| Indicator | RENX | VIVS |
|---|---|---|
| Relative Strength Index (RSI) | 50.58 | 28.24 |
| Support Level | $1.62 | N/A |
| Resistance Level | $2.10 | $0.30 |
| Average True Range (ATR) | 0.20 | 0.02 |
| MACD | 0.02 | 0.00 |
| Stochastic Oscillator | 46.02 | 16.30 |
RenX Enterprises Corp is engaged in real property development using purpose-built, prefabricated modules constructed from both wood and steel. The Company's operations mainly focused on the acquisition, entitlement, and development of residential properties in high-growth markets across the United States. These efforts included the direct acquisition of land, strategic investments in real estate entities, and joint venture partnerships targeting green, single-family, and multifamily housing projects. The company operates in four segments: real estate development, technology, compost sales, and logistics. The company generates from the compost sales.
VivoSim Labs Inc is a pharmaceutical and biotechnology services company focused on testing drugs and drug candidates in three-dimensional human tissue models of the liver and intestine. The Company provides liver and intestinal toxicology insights using its new approach methodologies and models and offers liver toxicology predictive screening and research services, as well as services to predict and study the intestinal side effect profiles of therapeutic candidates at all stages of drug development. Its 3D human tissue platform includes expertise in 3D organoids, such as spheroids, and proprietary cell culture techniques.